Detail akcie Kraig Biocraft online

Business Summary: Kraig Biocraft Laboratories, Inc. develops fibers using recombinant deoxyribonucleic acid (DNA) technology for commercial applications in technical textiles. The Company uses genetically engineered silkworms that produce spider silk proteins to create its recombinant spider silk. Its primary fiber technology includes natural and engineered variants of spider silk produced from domesticated mulberry silkworms. The Company’s products use the characteristics of spider silk, specifically dragline silk from Nephila clavipes and variants thereof. Its applications include performance apparel, workwear, filtration, luxury fashion, flexible composites, medical implants, cosmetics and more. Its products include Monster Silk, Dragon Silk, and other products. Its recombinant spider silk fiber blends the silk proteins found in spider silk with the native silkworm silk proteins. It also focuses on developing new recombinant silks and other protein-based fibers and materials.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Kraig Biocraft Laboratories Inc revenues was not reported. Net loss increased 11% to $2.8M. Higher net loss reflects General and Administrative increase of 26% to $1.9M (expense), Net change in unrealized depreciation on decrease of 46% to $77K (income), Interest income decrease of 91% to $6K (income).